You’ve Already Paid $6 Billion For Weight-Loss Drugs You Can’t Afford – The Lever

You’ve Already Paid $6 Billion For Weight-Loss Drugs You Can’t Afford  The Lever

The Billion-Dollar Taxpayer Math Behind The Ozempic Boom – The Lever

The Billion-Dollar Taxpayer Math Behind The Ozempic Boom  The Lever

Beyond compliance: The strategic role of PASS in rare disease therapy success

Post-authorisation safety studies (PASS) are often seen simply as a regulatory necessity, a checkbox that ensures…

Realising the opportunities for growth in the European orphan drug market

The European orphan drug market is growing and is already comparable in size and scope to…

Patients struggle with lack of consistent coverage for popular weight-loss drugs – Black Hills Pioneer

Patients struggle with lack of consistent coverage for popular weight-loss drugs  Black Hills Pioneer

Orphan drugs: How to avoid costly stock losses in Europe

With orphan drugs typically being high value, the potential risk of stock losses should be a…

FDA approves ARS’ neffy 1mg for paediatric anaphylaxis

FDA has granted approval for ARS Pharmaceuticals’ neffy 1mg for treating anaphylaxis in paediatric patients.

Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast. – Barron’s

Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast.  Barron’s

Trump Probes Long-Approved Meds; Could FDA Revoke Approvals? – Medscape

Trump Probes Long-Approved Meds; Could FDA Revoke Approvals?  Medscape

Amgen Challenges Novo Nordisk’s Ozempic And Eli Lilly’s Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials – Benzinga

Amgen Challenges Novo Nordisk’s Ozempic And Eli Lilly’s Zepbound As Its Monthly Weight Loss Drug MariTide…